Inventage Lab Inc is a Korea-based company principally engaged in the pharmaceutical business. The Company owns the platforms applied to the development and mass production of long-acting injections and drug delivery of genetic materials. The Company is engaged in the research, manufacture and sale of human medicines used for male pattern baldness, dementia, prostate cancer and others. It is also engaged in the research, manufacture and sale of veterinary medicines such as combination drugs, chemical castration agents and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
05/08/26	KRW 32,100.00	+2.56%	36,374
04/08/26	KRW 31,300.00	+10.41%	65,269
03/08/26	KRW 28,350.00	+4.04%	49,475
31/07/26	KRW 27,250.00	+10.10%	45,499
30/07/26	KRW 24,750.00	-0.20%	65,321

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 05/08/2026			5-day change	1st Jan Change
32,100.00 ^KRW	+2.56%		+16.73%	-61.88%

16/03	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
16/03	Inventage Lab, Inc. announced that it has received KRW 89.99724455 billion in funding from a group of investors	CI

Market Cap	426B 300M 259M 242M 222M 420M 28.48B 425M 2.84B 1.12B 14.25B 1.12B 1.1B 47.19B	P/E 2024	-11.5x	P/E 2025	-110x
Enterprise Value	421B 296M 256M 239M 220M 415M 28.12B 419M 2.81B 1.1B 14.07B 1.11B 1.09B 46.6B	EV / Sales 2024	106x	EV / Sales 2025	356x
Free-Float	73.58%	Yield 2024 *	-	Yield 2025	-

16/03	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
16/03	Inventage Lab, Inc. announced that it has received KRW 89.99724455 billion in funding from a group of investors	CI
09/03	Inventage Lab, Inc. announced that it has received KRW 8.5 billion in funding	CI
06/03	Inventage Lab, Inc. announced that it expects to receive KRW 37.25 billion in funding from a group of investors	CI
06/03	Inventage Lab, Inc. announced that it expects to receive KRW 8.5 billion in funding	CI
06/03	Inventage Lab, Inc. announced that it expects to receive KRW 52.74724455 billion in funding from a group of investors	CI
06/03	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
26/02	Inventage Lab, Inc. agreed to acquire an additional 12.79% stake in Quratis Inc. for KRW 13.5 billion.	CI
10/12	Inventage Lab Seeks Approval for Phase 2 Trial of Alopecia Drug in Australia	MT
22/09/25	Inventage Lab, Inc.(KOSDAQ:A389470) added to S&P Global BMI Index	CI
12/03/25	Inventage Lab, Inc. announced that it has received KRW 9.9999925 billion in funding from PEACE to S KOREA Co., Ltd	CI
12/03/25	Quratis Inc. announced that it has received KRW 10.0329 billion in funding from Inventage Lab, Inc.	CI
21/02/25	Quratis Inc. announced that it has received KRW 15 billion in funding from Inventage Lab, Inc.	CI

1 day	+2.56%
1 week	+16.73%
Current month	+17.80%
1 month	-15.75%
3 months	-49.29%
6 months	-58.09%
Current year	-61.88%

Inventage Lab, Inc. Stock

Stocks

A389470

KR7389470006

Pharmaceuticals

Valuation: Inventage Lab, Inc.

Chart: Inventage Lab, Inc.

Latest news : Inventage Lab, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Inventage Lab, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	23,000	32,650
1 month	22,650	40,800
Current year	22,650	101,700
1 year	22,650	101,700
3 years	9,400	101,700
5 years	8,440	101,700
10 years	8,440	101,700

Manager	Title	Age	Since
Ju-Hee Kim CEO	Chief Executive Officer	52	14/05/2015
Byeong-Yul Jeong DFI	Director of Finance/CFO	55	-
Chan-Hee Jeon CTO	Chief Tech/Sci/R&D Officer	57	-

Director	Title	Age	Since
Ju-Hee Kim BRD	Director/Board Member	52	14/05/2015
Choong-Ho Ryu BRD	Director/Board Member	56	-
Dong-Hoon Kim BRD	Director/Board Member	56	-

Date	Insider	Type	Quantity	% Market Cap.
8/8/25	Dong Seok Park	Fiscal year	8,000	0.0796%
8/8/25	Se Yeon Kim	Fiscal year	10,000	0.0996%
8/8/25	Dong Seok Park	Fiscal year	8,000	0.0796%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INVENTAGE LAB, INC.	+2.56%	+16.73%	+4.73%	+89.83%	291M
ELI LILLY AND COMPANY	+4.35%	-4.04%	+51.60%	+155.71%	995B
JOHNSON & JOHNSON	+1.11%	-2.73%	+51.27%	+49.21%	614B
ABBVIE INC.	+0.44%	-6.98%	+23.35%	+62.91%	431B
ROCHE HOLDING AG	+1.96%	+0.83%	+42.80%	+37.70%	353B
NOVARTIS AG	-0.11%	-4.07%	+30.37%	+38.52%	293B
ASTRAZENECA PLC	+2.52%	-8.36%	+7.27%	+10.56%	245B
AMGEN INC.	+3.33%	+3.83%	+34.12%	+59.12%	210B
NOVO NORDISK A/S	-4.32%	-12.94%	-3.79%	-46.07%	210B
GILEAD SCIENCES, INC.	-2.96%	-1.06%	+16.77%	+62.79%	168B
Average	+0.95%	-1.55%	+25.85%	+52.03%	351.85B
Weighted average by Cap.	+1.67%	-5.89%	+36.34%	+71.84%

	2024	2025
Net sales	1.78B 1.25M 1.09M 1.01M 930K 1.76M 119M 1.78M 11.89M 4.67M 59.61M 4.71M 4.6M 197M	2.94B 2.07M 1.79M 1.67M 1.53M 2.9M 196M 2.93M 19.59M 7.69M 98.25M 7.76M 7.59M 325M
Net income	-17B -11.94M -10.34M -9.64M -8.87M -16.74M -1.14B -16.93M -113M -44.48M -568M -44.86M -43.87M -1.88B	-8.46B -5.94M -5.15M -4.8M -4.41M -8.33M -565M -8.43M -56.39M -22.13M -283M -22.32M -21.83M -937M
Net Debt	-23.96B -16.84M -14.59M -13.6M -12.51M -23.61M -1.6B -23.87M -160M -62.71M -801M -63.25M -61.86M -2.65B	-5.33B -3.74M -3.24M -3.02M -2.78M -5.25M -356M -5.31M -35.52M -13.94M -178M -14.06M -13.75M -590M